News
Revolution Medicines’ Daraxonrasib Enters EMA Phased Review for Pancreatic Cancer
Daraxonrasib has already received orphan medicinal product designation from the EMA for the treatment of pancreatic cancer and has been recognized as a high-priority candidate under the agency’s Cancer Medicines Pathfinder project.
imphoenix82
- July 7, 2026
- 0 Comments
- 13 Views
-
